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Anti-Obesity Medical Devices
Hassan M. Heshmati
Abstract
Obesity is a major health problem worldwide responsible for increased mor-
bidity/mortality and high cost for the society. Management of obesity requires 
multidisciplinary approaches including diet, food supplement, exercise, behavior 
change, drug, medical device, gut microbiome manipulation, and surgery. Anti-
obesity medical devices are an option for subjects who have not responded to more 
conservative medical treatments but want an alternative to surgery. Compared to 
bariatric surgery, they have the advantage of being less invasive, easier to perform, 
and reversible. In the United States of America (USA), based on the expected 
weight loss, the Center for Devices and Radiological Health (CDRH) of the Food 
and Drug Administration (FDA) categorizes anti-obesity medical devices as weight-
loss devices or weight-management devices. The weight-loss devices include gastric 
band devices, gastric space-occupying devices, and gastric emptying devices. 
The weight-management devices include oral removable palatal space-occupying 
devices and ingested transient gastric space-occupying devices. The effectiveness, 
safety, and cost of anti-obesity medical devices vary considerably by the type 
of medical device. Their use should always be combined with lifestyle changes. 
Considering the large market size of obesity treatment, anti-obesity medical devices 
can play a major role in the management of obesity.
Keywords: medical devices, obesity, weight loss, weight management
1. Introduction
Obesity is excess body weight for a given height, defined by a body mass index 
(BMI) ≥ 30 kg/m2. In some Asian countries (e.g., Japan), the threshold to define 
obesity is lower (25 kg/m2). Obesity is a major health problem worldwide associated 
with increased morbidity/mortality and high cost for the society. The prevalence 
of obesity has doubled in more than 70 countries since 1980. The number of adult 
subjects with obesity is around 700 million worldwide. Nearly 4 million subjects die 
each year from the consequences of obesity. The annual cost of obesity is more than 
$2 trillion [1–3].
Management of obesity requires multidisciplinary approaches including diet, 
food supplement, exercise, behavior change, drug, medical device, gut microbiome 
manipulation, and surgery [1, 4–9]. The annual obesity treatment market is around 
$6 billion. In the USA, among subjects with obesity, only 2% receive drug therapy 
and less than 1% who are eligible for bariatric surgery benefits from it. The reasons 
for these undertreatment rates are mainly related to adverse effects/complications 
and cost of drugs and bariatric surgery.
Medical devices available 100 years ago were limited to stethoscope, original 
medical X-ray imaging device, and electrocardiograph [10]. Over the past several 
Weight Management
2
decades, the number of medical devices has increased exponentially. Anti-obesity 
medical devices are positioned to bridge the gap between more conservative treat-
ments (e.g., lifestyle) and more aggressive interventions (e.g., bariatric surgery). 
Compared to bariatric surgery, they have the advantage of being less invasive, 
easier to perform, and reversible. Anti-obesity medical devices are available upon 
prescription or as over-the-counter products.
2. Heterogeneity of anti-obesity medical devices
Anti-obesity medical devices represent a heterogeneous family of devices in 
terms of presentation, usage/administration, mechanism of action, effectiveness, 
safety, regulation, availability, and cost [8, 11–14]. The devices can be as different 
as an intragastric balloon, a stomach aspiration system, or particles administered 
orally in capsule.
3. General characteristics of anti-obesity medical devices
Unlike anti-obesity drugs that act chemically through specific receptors, 
anti-obesity medical devices act rather mechanically. They do not have systemic 
absorption, specific metabolism, or receptors. Their research and development 
pattern follow specific models. The terminology used for medical devices differs 
slightly from that used for drugs (e.g., sham instead of placebo, effectiveness 
instead of efficacy). With some medical devices, it is not possible to use a sham 
for ethical and/or technical reasons. Compared to drugs, medical devices have 
different effectiveness dynamics. Unlike drugs, for some anti-obesity medical 
devices, there is no compliance issue with the device use since the device is placed 
in the body for several months and there is no need for repeated administration 
that might be affected by the subject’s discipline. Because there is no systemic 
absorption, there are no side effects related to the impact of medical devices on 
different organs through the bloodstream. The regulatory systems ruling anti-
obesity medical devices are based on short product life cycles. The marketing and 
sales of anti-obesity medical devices are based on different models as compared 
to drugs.
4. Mechanism of action of anti-obesity medical devices
Anti-obesity medical devices can cause weight loss through different mecha-
nisms by acting at different levels.
4.1 Decrease in food intake
Although the primary impact of the anti-obesity medical devices is mechani-
cal, the final effect may be achieved through changes in several factors controlling 
appetite and food intake, especially the gastrointestinal hormones (e.g., decrease in 
ghrelin, increase in glucagon-like peptide-1).
4.1.1 Oral cavity
An anti-obesity medical device can decrease the food intake by limiting the bite 
size in the oral cavity.
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4.1.2 Stomach
An anti-obesity medical device can decrease the food intake by reducing the 
available stomach volume.
4.1.3 Others
Other levels of impact to achieve food intake reduction are possible and have 
been or will be investigated.
4.2 Decrease in available/absorbed nutrient
4.2.1 Stomach
An anti-obesity medical device can decrease the amount of available nutrient by 
removing part of the gastric contents.
4.2.2 Intestine
An anti-obesity medical device can decrease the absorbed nutrient by bypassing 
part of the intestine.
5. Challenges in developing anti-obesity medical devices
The main challenges in the development of anti-obesity medical devices are due 
to lack of unique regulatory guidance and disparities in time and cost of approval 
processes in different countries.
6. Regulation and approval/clearance of anti-obesity medical devices
The regulation of anti-obesity medical devices varies by countries or group of 
countries. There are important differences in the regulatory processes, cost, and 
time to approval between the USA and Europe [15].
Over-the-counter anti-obesity medical devices may or may not need regulation 
and approval/clearance depending on the devices and countries.
6.1 USA
In the USA, the regulation of medical devices is centralized since 1976 through 
the FDA. This centralized process allows a better coordination and enforcement of 
rules. The CDRH is in charge of approval/clearance of anti-obesity medical devices. 
There are three regulatory classes of medical devices: Class I (low risk), Class II 
(moderate risk), and Class III (high risk). Based on the expected weight loss, two 
categories of anti-obesity medical devices have been defined: weight-loss devices 
(“more” weight loss) and weight-management devices (“less” weight loss). The 
approval/clearance is through premarket notification process [510(k)] or premarket 
approval (PMA) process and is based on safety and effectiveness.
A new guidance using benefit-risk approaches is in preparation by the CDRH 
taking into account the weight loss (extent and duration), the rate of responders 
(≥ 5% weight loss), the reduction of comorbidities (e.g., hypertension, dyslipid-
emia, type 2 diabetes), and the safety [rate and severity of adverse events (AEs)].
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6.2 Europe
Since its formation in 1993, the European Union (EU), currently a group of 27 
countries (after the recent removal of the United Kingdom), has established rules for 
the approval of medical devices. Anti-obesity medical devices are regulated under 
directive 93/42/EC. There are four regulatory classes of medical devices: Class I (low 
risk), Class IIa (low-moderate risk), Class IIb (moderate-high risk), and Class III 
(high risk). Each member country has a regulatory entity called Competent Authority 
(CA). The CA certifies/notifies entities called Notified Bodies (NBs) in each country. 
The NBs are private, for-profit companies responsible for conformity assessment 
and CE (Conformité Européenne) mark. There are over 50 NBs in the EU. The NBs 
contract with the manufacturers to supply the CE mark and the approval is based on 
safety and performance. Clinical effectiveness is not a requirement. An anti-obesity 
medical device with a CE mark can be marketed in any EU member country.
In the EU, the approval process is more flexible, faster, and less expensive in 
comparison to the USA.
6.3 Other countries
Other countries have different regulatory procedures. The approval process has 
varying degrees of sophistication and challenges. In Japan for example, the appli-
cation is processed by the Pharmaceutical and Medical Device Agency (PMDA). 
Although the Japanese market is very attractive for foreign manufacturers, the 
approval process is complicated, long, and expensive due to multiple factors (e.g., 
lack of translated documents from Japanese, need to perform specific and costly 
studies in the Japanese population).
Several countries accept the FDA approval/clearance or the CE mark.
7. Approved/cleared anti-obesity medical devices
Several anti-obesity medical devices have been approved/cleared in the USA, 
in the EU, and in other countries. Some devices have been approved first in the EU 
before being approved several years later in the USA. This section focuses on anti-
obesity medical devices regulated in the USA.
Below are the anti-obesity medical devices approved/cleared in the USA 
(Table 1). Their use should always be in conjunction with lifestyle recommenda-
tions on diet and exercise.
Medical device Approval date Indication
Lap-Band® June 5, 2001 Weight-loss device (BMI ≥ 35 kg/m2)
Orbera™ Intragastric Balloon 
System
August 5, 2015 Weight-loss device (BMI 30–40 kg/m2)
AspireAssist® June 14, 2016 Weight-loss device (BMI 35–55 kg/m2)
Obalon Balloon System September 8, 2016 Weight-loss device (BMI 30–40 kg/m2)
SmartByte Device May 18, 2017 Weight-management device (BMI 27–35 kg/m2)
Plenity™ April 12, 2019 Weight-management device (BMI 25–40 kg/m2)
TransPyloric Shuttle April 16, 2019 Weight-loss device (BMI 30–40 kg/m2)
Table 1. 
Approved/cleared anti-obesity medical devices in the USA ranked by approval date.
5Anti-Obesity Medical Devices
DOI: http://dx.doi.org/10.5772/intechopen.91697
7.1 Weight-loss devices
7.1.1 Gastric band devices
7.1.1.1 Lap-Band®
Lap-Band® (BioEnterics Corporation) is an adjustable silicone band placed 
laparoscopically around the proximal stomach immediately below the gastro-
esophageal junction and attached to a subcutaneous reservoir (Figure 1). The level 
of pressure is adjusted by varying the amount of fluid that is inserted into the band. 
The technique is reversible, has low procedural risk, and can be performed in an 
outpatient setting. Lap-Band® can be revised and/or replaced as needed. The pres-
sure imposed to the proximal stomach causes early satiety and a decrease in food 
intake with subsequent weight loss [8].
In the pivotal study, 292 subjects (247 females, 45 males, mean BMI = 47.4 
kg/m2) were implanted with Lap-Band® and had follow-up evaluations for 
36 months. The primary effectiveness endpoint, assessed in the per protocol 
population at Month 36, was the excess weight loss. Safety analysis also included 
an additional seven subjects who previously received a similar device. At Month 
36, the excess weight loss was 36.2%, relatively stable over the previous 18 months 
(the weight loss was 18.0%). AEs were observed in 266 subjects (89.0%). Most 
AEs were of gastrointestinal origin (mainly nausea/vomiting, gastroesophageal 
reflux, and abdominal pain, mild in the majority of cases). Serious AEs (SAEs) 
were observed in 16 subjects (5.4%), mainly port leakage and 2 deaths (unrelated 
to device).
Overall, Lap-Band® is relatively safe and has a strong effectiveness. The device 
was approved by the FDA in June 2001. It is indicated for weight loss in severe obe-
sity with BMI ≥ 40 kg/m2 or obesity with BMI ≥ 35 kg/m2 in the presence of one or 
more severe comorbidities, in conjunction with lifestyle recommendations, in sub-
jects who failed to respond to diet, exercise, and behavior change. It is contraindi-
cated in several conditions including pregnancy, non-adult subjects, inflammatory 
diseases of the gastrointestinal tract, upper gastrointestinal bleeding conditions, 
Figure 1. 
Lap-Band® (BioEnterics Corporation—Picture downloaded from the internet).
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portal hypertension, and severe cardiopulmonary diseases (non-exhaustive list). 
Complications include proximal gastric enlargement, erosion or migration of the 
band, and leaks of the band system (non-exhaustive list).
7.1.2 Gastric space-occupying devices
7.1.2.1 Orbera™ Intragastric balloon system
Orbera™ Intragastric Balloon System (Apollo Endosurgery, Inc.) is a balloon 
made of silicone placed endoscopically in the stomach (Figure 2). The balloon is 
filled with saline mixed with methylene blue (450–700 mL). The methylene blue 
is a marker for balloon dysfunction. In case of balloon rupture, the methylene blue 
will be systematically absorbed and change the color of urine to blue. The procedure 
is minimally invasive and can be performed in an outpatient setting. The balloon 
is removed endoscopically after 6 months. By occupying gastric volume, Orbera™ 
Intragastric Balloon System causes early satiety and a decrease in food intake with 
subsequent weight loss [8, 11, 13, 14].
In the pivotal study, 255 subjects (229 females, 26 males, mean BMI = 35.3 
kg/m2) were randomized into Orbera™ Intragastric Balloon System (n = 125) or 
control (no intragastric intervention, n = 130) arms for 6 months and 6 months 
follow-up after Orbera™ Intragastric Balloon System removal. Safety analysis also 
included an additional 35 run-in, non-randomized subjects who received Orbera™ 
Intragastric Balloon System. All subjects were given lifestyle recommendations. 
The co-primary effectiveness endpoints, assessed in the modified intention-
to-treat (mITT) population at Month 9, were the excess weight loss in Orbera™ 
Intragastric Balloon System arm and a significantly greater weight loss in Orbera™ 
Intragastric Balloon System arm compared to control arm. At Month 9, the excess 
weight loss was 26.5% in Orbera™ Intragastric Balloon System arm, and the weight 
losses were 9.1 and 3.4% in Orbera™ Intragastric Balloon System and control arms, 
respectively. The study did not meet the first co-primary effectiveness endpoint 
but met the second co-primary effectiveness endpoint. At Month 6, the weight 
losses were 10.2 and 3.3% in Orbera™ Intragastric Balloon System and control 
arms, respectively. A total of 810 device-related AEs was observed (mainly nau-
sea/vomiting, gastroesophageal reflux, and abdominal pain, mild or moderate in 
the majority of cases). Fourteen device- or procedure-related SAEs were observed, 
mainly device intolerance but no death.
Figure 2. 
Orbera™ Intragastric Balloon System (Apollo Endosurgery, Inc.—Picture downloaded from the internet).
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Overall, Orbera™ Intragastric Balloon System is relatively safe and has a strong 
effectiveness. The device was approved by the FDA in August 2015. It is indicated 
for weight loss in obesity with BMI between 30 and 40 kg/m2, in conjunction with 
lifestyle recommendations, in subjects who failed to respond to diet, exercise, and 
behavior change. It is contraindicated in several conditions including pregnancy, 
non-adult subjects, prior bariatric surgery, inflammatory diseases of the gastro-
intestinal tract, upper gastrointestinal bleeding conditions, and liver deficiency 
(non-exhaustive list). Complications include balloon migration, intestinal obstruc-
tion, gastric ulcer, and gastric perforation (non-exhaustive list).
7.1.2.2 Obalon Balloon System
Obalon Balloon System (Obalon Therapeutics, Inc.) is a swallowable balloon 
made of nylon and polyethylene contained within a gelatin capsule (attached to 
a thin inflation catheter) that is taken orally. The correct position of the capsule 
is confirmed with fluoroscopy. The capsule disintegrates in the stomach and 
releases the balloon. The balloon is filled with air (250 cc of nitrogen and sulfur 
hexafluoride gas mixture). Up to three balloons can be placed in the same session or 
sequentially over a 6-month period (Figure 3). The procedure is minimally invasive 
and can be performed in an outpatient setting without endoscopy. The balloon 
is removed endoscopically after 6 months. By occupying gastric volume, Obalon 
Balloon System causes early satiety and a decrease in food intake with subsequent 
weight loss [8, 13, 14].
In the pivotal study, 387 subjects (341 females, 46 males, mean BMI = 35.2 kg/m2) 
were randomized into Obalon Balloon System (n = 198) or control (sham capsule, 
n = 189) arms for 6 months. At Month 6, the eligible control arm subjects were 
permitted to crossover and receive Obalon Balloon System for 6 months. All subjects 
were given lifestyle recommendations. The co-primary effectiveness endpoints, 
assessed in the mITT population at Month 6, were a significantly greater weight loss 
in Obalon Balloon System arm compared to control arm (super-superiority) and 
the responder rate at 5% weight loss in Obalon Balloon System arm. Device-related 
safety analysis also included 138 subjects who switched at Month 6 from control to 
Obalon Balloon System. At Month 6, the weight losses were 6.6 and 3.4% in Obalon 
Balloon System and control arms, respectively, and the responder rate at 5% weight 
loss in Obalon Balloon System arm was 62.1%. The study met both co-primary effec-
tiveness endpoints. Most device-related AEs were of gastrointestinal origin (mainly 
abdominal pain and nausea/vomiting, mild in the majority of cases), observed in 
Figure 3. 
Obalon Balloon System (Obalon Therapeutics, Inc.—Picture downloaded from the internet).
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300 subjects (89.3%). Device- or procedure-related SAEs were observed in one 
subject (0.3%), a case of peptic ulcer disease.
Overall, Obalon Balloon System is relatively safe and has a modest effectiveness. 
The device was approved by the FDA in September 2016. It is indicated for weight 
loss in obesity with BMI between 30 and 40 kg/m2, in conjunction with lifestyle 
recommendations, in subjects who failed to respond to diet, exercise, and behavior 
change. It is contraindicated in several conditions including pregnancy, non-adult 
subjects, prior bariatric surgery, inflammatory diseases of the gastrointestinal tract, 
gastric diseases, and eating disorders (non-exhaustive list). Complications include 
balloon migration, intestinal obstruction, gastric ulcer, and gastric perforation 
(non-exhaustive list).
7.1.2.3 TransPyloric Shuttle
TransPyloric Shuttle (BAROnova, Inc.) is a device placed endoscopically in 
the stomach (Figure 4). It is not strictly a balloon but functions like a balloon. It 
has two asymmetrical bulbs made of silicone connected by a flexible catheter. The 
procedure is minimally invasive and can be performed in an outpatient setting. 
The shuttle is removed endoscopically after 12 months. By creating intermit-
tent obstruction to gastric outflow that delays gastric emptying, TransPyloric 
Shuttle causes early satiety and a decrease in food intake with subsequent weight 
loss [8, 13].
In the pivotal study, 270 subjects (252 females, 18 males, mean BMI = 36.6 kg/m2) 
were randomized into TransPyloric Shuttle (n = 181) or control (sham endoscopic 
procedure, n = 89) arms for 12 months. The TransPyloric Shuttle was successfully 
placed in 171 subjects. The study also included an additional 32 open-label subjects 
who received TransPyloric Shuttle. All subjects were given lifestyle recommenda-
tions. The co-primary effectiveness endpoints, assessed in the per protocol popula-
tion at Month 12, were a significantly greater weight loss in TransPyloric Shuttle arm 
compared to control arm and the responder rate at 5% weight loss in TransPyloric 
Shuttle arm. At Month 12, the weight losses were 9.5 and 2.8% in TransPyloric 
Shuttle and control arms, respectively, and the responder rate at 5% weight loss in 
TransPyloric Shuttle arm was 66.8%. The study met both co-primary effectiveness 
endpoints. Most device-related AEs were of gastrointestinal origin (mainly nausea/
vomiting, abdominal pain, and dyspepsia, mild or moderate in the majority of 
Figure 4. 
TransPyloric Shuttle (BAROnova, Inc.—Picture downloaded from the internet).
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cases), observed in 200 subjects (98.5%). Device- or procedure-related SAEs were 
observed in six subjects (3.0%), mainly device impaction but no death.
Overall, TransPyloric Shuttle is relatively safe and has a strong effectiveness. 
The device was approved by the FDA in April 2019. It is indicated for weight loss 
in obesity with BMI between 35 and 40 kg/m2 or obesity with BMI between 30 
and < 35 kg/m2 in the presence of one or more comorbidities, in conjunction with 
lifestyle recommendations, in subjects who failed to respond to diet, exercise, 
and behavior change. It is contraindicated in several conditions including preg-
nancy, non-adult subjects, prior bariatric surgery, inflammatory diseases of the 
gastrointestinal tract, gastric diseases, and eating disorders (non-exhaustive list). 
Complications include device impaction and gastric ulcer (non-exhaustive list).
7.1.3 Gastric emptying devices
7.1.3.1 AspireAssist®
AspireAssist® (Aspire Bariatrics, Inc.) is a device attached to a percutaneous 
endoscopic gastrostomy tube implanted endoscopically (Figure 5). It allows the 
aspiration of gastric contents 20–30 minutes after each major meal (a meal contain-
ing more than 200 calories). Thorough chewing of food is required to facilitate 
aspiration with the 6-mm-diameter tube. The procedure is minimally invasive and 
can be performed in an outpatient setting. The device is removed when the desired 
body weight is reached. By allowing the removal of approximately 30% of ingested 
calories over 5–10 minutes, AspireAssist® causes decreased absorption of gastroin-
testinal nutrients with subsequent weight loss [8, 11–14].
In the pivotal study, 171 subjects (149 females, 22 males, mean BMI = 41.6 kg/
m2) were randomized into AspireAssist® (n = 111) or control (no intragastric 
intervention, n = 60) arms for 12 months. All subjects were given lifestyle recom-
mendations. The co-primary effectiveness endpoints, assessed in the mITT popula-
tion at Month 12, were a significantly greater excess weight loss in AspireAssist® 
arm compared to control arm (super-superiority) and the responder rate at 25% 
excess weight loss in AspireAssist® arm. At Month 12, the excess weight losses were 
31.5 and 9.8% in AspireAssist® and control arms, respectively, and the responder 
rate at 25% excess weight loss in AspireAssist® arm was 56.8%. The study met the 
first co-primary effectiveness endpoint but not the second co-primary effectiveness 
endpoint. At Month 12, the weight losses were 12.1 and 3.6% in AspireAssist® and 
Figure 5. 
AspireAssist® (Aspire Bariatrics, Inc.—Picture downloaded from the internet).
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control arms, respectively. Device- or procedure-related AEs were observed in 93 
subjects (83.8%, mainly peristomal granulation tissue, abdominal pain, and nausea/
vomiting, mild in the majority of cases). Device- or procedure-related SAEs were 
observed in four subjects (3.6%), including peritonitis but no death.
Overall, AspireAssist® is relatively safe and has a strong effectiveness. The 
device was approved by the FDA in June 2016. It is indicated for weight loss in 
obesity with BMI between 35 and 55 kg/m2, in conjunction with lifestyle rec-
ommendations, in subjects who failed to respond to non-surgical weight-loss 
therapy. It is contraindicated in several conditions including pregnancy, non-adult 
subjects, upper gastrointestinal bleeding conditions, chronic abdominal pain, 
severe cardiopulmonary diseases, and eating disorders (non-exhaustive list). 
Complications include skin irritation, infection, and electrolyte abnormalities 
(non-exhaustive list).
7.2 Weight-management devices
7.2.1 Oral removable palatal space-occupying devices
7.2.1.1 SmartByte Device
SmartByte Device (Scientific Intake) is an oral device occupying space on 
the upper palate. It includes a temperature-recording sensor to monitor usage 
(Figure 6). It is worn in mouth during meal consumption. The device is renewed 
every 12 months. By creating limited bite size and slower eating, SmartByte Device 
causes a decrease in food intake with subsequent weight loss [16].
In the pivotal study, 173 subjects (BMI between 26 and 36 kg/m2) were random-
ized into SmartByte Device (n = 102) or control (no oral intervention, n = 71) arms 
for 4 months. All subjects were given lifestyle recommendations. The primary 
effectiveness endpoint, assessed in the ITT population at Month 4, was a greater 
responder rate at 5% weight loss in SmartByte Device arm compared to control arm. 
At Month 4, the responder rates at 5% weight loss were 20.6 and 5.6% in SmartByte 
Device and control arms, respectively. The study did not meet the primary effec-
tiveness endpoint. At Month 4, the weight losses were 1.7 and 0.4% in SmartByte 
Device and control arms, respectively. Device-related AEs were observed in five 
subjects (4.9%, including two episodes of transient choking on food). No device-
related SAEs were observed.
Figure 6. 
SmartByte Device (Scientific Intake—Picture downloaded from the internet).
11
Anti-Obesity Medical Devices
DOI: http://dx.doi.org/10.5772/intechopen.91697
Overall, SmartByte Device is safe and has a weak effectiveness. The device 
was cleared by the FDA in May 2017. It is indicated to aid in weight management 
in overweight and obesity with BMI between 27 and 35 kg/m2, in conjunction 
with lifestyle recommendations. It is contraindicated in pregnancy and eating 
disorders. Complications include choking on food and mouth soreness (non-
exhaustive list).
7.2.2 Ingested transient gastric space-occupying devices
7.2.2.1 Plenity™
Plenity™ (Gelesis, Inc.) is a superabsorbent hydrogel (cellulose and citric acid, 
forming a three-dimensional matrix) administered orally in capsules with 500 mL 
of water (three capsules, 20–30 minutes before lunch and dinner). The hydrogel 
particles hydrate up to 100 times their initial weight in the stomach and intestine 
(Figure 7). The particles mix with ingested food and create a larger volume with 
higher elasticity and viscosity. The particles degrade in the colon and are eliminated 
in the feces. By creating a larger volume with higher elasticity in the stomach and 
intestine, Plenity™ causes early satiety and a decrease in food intake with subse-
quent weight loss [17].
In the pivotal study, 436 subjects (245 females, 191 males, mean BMI = 33.8 kg/m2) 
were randomized into Plenity™ (n = 223) or control (sham capsule, n = 213) arms for 
6 months. All subjects were given lifestyle recommendations. The co-primary effective-
ness endpoints, assessed in the ITT population (multiple imputation) at Month 6, were 
a significantly greater weight loss in Plenity™ arm compared to control arm (super-
superiority) and the responder rate at 5% weight loss in Plenity™ arm. At Month 6, 
the weight losses were 6.4 and 4.4% in Plenity™ and control arms, respectively, and 
the responder rate at 5% weight loss in Plenity™ arm was 58.6%. The study did not 
meet the first co-primary effectiveness endpoint but met the second co-primary 
effectiveness endpoint. Most device-related AEs were of gastrointestinal origin (mainly 
abdominal distension, diarrhea, infrequent bowel movements, and flatulence, mild in 
the majority of cases), observed in 84 subjects (37.7%). No device-related SAEs were 
observed.
Overall, Plenity™ is safe and has a modest effectiveness. The device was 
cleared by the FDA in April 2019. It is indicated to aid in weight management in 
overweight and obesity with BMI between 25 and 40 kg/m2, in conjunction with 
lifestyle recommendations. It is contraindicated in pregnancy, non-adult subjects, 
and history of allergic reaction to the components of Plenity™ capsule. No relevant 
complications have been reported.
Figure 7. 
Plenity™ (Gelesis, Inc.—Picture downloaded from the internet).
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Comparative effectiveness of the above anti-obesity medical devices is reported 
in Table 2.
Relevant complications (non-exhaustive list), some being very rare, of the above 
anti-obesity medical devices are reported in Table 3.
Cost of the above anti-obesity medical devices is reported in Table 4.
Medical device Treatment 
duration
Relevant complication
Lap-Band® 36 months Proximal gastric enlargement, band erosion or 
migration, system leaks
AspireAssist® 12 months Skin irritation, infection, electrolyte abnormalities
Orbera™ Intragastric Balloon 
System
6 months Balloon migration, intestinal obstruction, gastric 
ulcer, gastric perforation
TransPyloric Shuttle 12 months Device impaction, gastric ulcer
Obalon Balloon System 6 months Balloon migration, intestinal obstruction, gastric 
ulcer, gastric perforation
Plenity™ 6 months None
SmartByte Device 4 months Choking on food, mouth soreness
Table 3. 
Relevant complications of the approved/cleared anti-obesity medical devices in the USA in pivotal studies.
Medical device Average cost (Range)
Lap-Band® $15,000 ($10,000–$30,000)
AspireAssist® $10,000 ($7,000–$13,000)
Orbera™ Intragastric Balloon System $6,000 ($3,000–$9,000)
TransPyloric Shuttle To be determined
Obalon Balloon System $8,000 ($6,000–$9,000)
Plenity™ $100/month
SmartByte Device $500
Table 4. 
Cost of the approved/cleared anti-obesity medical devices in the USA.
Medical device Treatment duration Total body weight loss
Lap-Band® 36 months 18.0%
AspireAssist® 12 months 12.1%
Orbera™ Intragastric Balloon System 6 months 10.2%
TransPyloric Shuttle 12 months 9.5%
Obalon Balloon System 6 months 6.6%
Plenity™ 6 months 6.4%
SmartByte Device 4 months 1.7%
Table 2. 
Approved/cleared anti-obesity medical devices in the USA ranked by extent of total body weight loss in pivotal 
studies.
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8. Anti-obesity medical devices withdrawn from the market in the USA
Several anti-obesity medical devices have been withdrawn by the manufacturers 
from the market in the USA after approval by the FDA (e.g., Maestro Rechargeable 
System, Realize Adjustable Gastric Band, ReShape Integrated Dual Balloon System, 
Garren Gastric Bubble).
9.  Anti-obesity medical devices under investigation or pending  
approval
Several anti-obesity medical devices are currently in development in different 
countries (e.g., Epitomee Device [18]).
EndoBarrier® has obtained a CE mark in the EU but its approval in the USA has 
been challenged for safety reasons [8, 11–14].
10. Over-the-counter anti-obesity medical devices
A variety of anti-obesity medical devices are available as over-the-counter 
products (e.g., NozNoz, slow control fork, slipper genie).
11. Conclusions
Anti-obesity medical devices represent a heterogenous family of devices in terms of 
presentation, usage/administration, mechanism of action, effectiveness, safety, regu-
lation, availability, and cost. They offer an attractive approach in managing obesity. 
Anti-obesity medical devices are positioned to bridge the gap between more conser-
vative treatments (e.g., lifestyle) and more aggressive interventions (e.g., bariatric 
surgery). Their use should always be combined with lifestyle changes.
Considering the large market size of obesity treatment and the small percentage 
of subjects treated with drugs or bariatric surgery, anti-obesity medical devices can 
play a major role in the management of obesity.
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